Skip to content
value.today
XBiotech Inc. logo

XBiotech Inc.

XBIT
$61 Mmarket cap on Oct 20, 2026-52.7% since Jan 2024
Compare
World rank
#20,616
Revenue
—
For year ending December-2025
Net income
$-46 M
SEC filing
Employees
94
As on June 2021
value.today research

XBiotech Inc. in brief

XBiotech Inc. is a listed company in the Biotechnology industry, based in Austin, Texas, USA. Its market value was $61 M on 20 October 2026, which makes it the 20,616th largest listed company in the world and the 3,773rd largest in the USA on this site. It employs about 94 people and Jan-Paul Simard is its chief executive. Its shares trade under the symbol XBIT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About XBiotech Inc.

Xbiotech is a Clinical Stage Biopharmaceutical company. The company annual revenue is 10.5 million USD. The headquarters is in USA.

XBiotech Inc. timeline

2 events, 2014–2015
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2015
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 16 April 2015; shares registered for exchange trading on 14 April 2015.

Events of XBiotech Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$214 M$428 M$642 M$855 M2020202120222023202420252026

World rank over time

▼ down 11,937 places since 2020
2020-01-01: #8712#8,71220202021-01-01: #11589#11,58920212022-01-07: #15854#15,85420222022-12-25: #21986#21,98620222023-07-30: #19455#19,45520232024-01-05: #20146#20,14620242026-03-08: #10440#10,44020262026-08-01: #18453#18,45320262026-10-06: #20372#20,37220262026-10-20: #20649#20,6492026

Rank in USA: #2,121 (Jan 2020) · #2,825 (Jan 2021) · #3,314 (Jan 2022) · #4,334 (Dec 2022) · #3,838 (Jul 2023) · #3,531 (Jan 2024) · #2,041 (Mar 2026) · #3,606 (Aug 2026) · #3,717 (Oct 2026) · #3,777 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.4×
Free cash flow yield
-65.9%
Net margin
—
Operating margin
—
Return on equity
-32.4%
Liabilities / assets
6.5%
Revenue growth
-78.2%
R&D / revenue
786.5%
Profit per employee
$-484 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-21M—FY18Fiscal year ending Dec 2019: revenue —, net income $669M—FY19Fiscal year ending Dec 2020: revenue $44M, net income $-11M$44MFY20Fiscal year ending Dec 2021: revenue $18M, net income $-17M$18MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-33M$4MFY22Fiscal year ending Dec 2023: revenue —, net income $-25M—FY23Fiscal year ending Dec 2024: revenue —, net income $-39M—FY24Fiscal year ending Dec 2025: revenue —, net income $-46M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-56M$-46M—
Dec 2024——$-42M$-39M—
Dec 2023——$-38M$-25M—
Dec 2022$4M-78.2%$-34M$-33M-820.4%
Dec 2021$18M-58.2%$-25M$-17M-94.7%
Dec 2020$44M—$-18M$-11M-25.5%
Dec 2019——$-31M$669M—
Dec 2018——$-21M$-21M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-40M$0M$-40M$-1.49—
Dec 2024$-31M$1M$-32M$-1.26—
Dec 2023$-19M$0M$-19M$-0.81—
Dec 2022$-15M$1M$-15M$-1.08—
Dec 2021$69M$4M$66M$-0.58—
Dec 2020$-65M$4M$-69M$-0.36—
Dec 2019$-18M$0M$-18M$14.44—
Dec 2018$-17M$0M$-17M$-0.59—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-11M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-6M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-27M—Dec ’25Three months to Mar 2026: revenue —, net income $-6M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of XBiotech Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-56 M
Net income
$-46 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$150 M
Total liabilities
$10 M
Total equity
$140 M

As of December-2025

Top 34 institutional investors in XBiotech Inc.#

As of Sep 30, 2026
34 institutions held 1.9 M shares (about 6.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in XBiotech Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.317,527-3,619 (-1.13%)1.04%$1 MNov 13, 2026
2Geode Capital Management, LLC214,1160 (0.00%)0.70%$0 MNov 6, 2026
3Vanguard Capital Management LLC200,1820 (0.00%)0.66%$0 MNov 13, 2026
4RBF Capital, LLC198,5010 (0.00%)0.65%$0 MNov 13, 2026
5Vanguard Fiduciary Trust Co125,691+33,326 (+36.08%)0.41%$0 MNov 13, 2026
6Morgan Stanley123,988-23,892 (-16.16%)0.41%$0 MNov 13, 2026
7Bridgeway Capital Management, LLC98,4470 (0.00%)0.32%$0 MNov 16, 2026
8State Street Corp73,0060 (0.00%)0.24%$0 MNov 12, 2026
9Renaissance Technologies LLC67,355+25,692 (+61.67%)0.22%$0 MNov 12, 2026
10Northern Trust Corp60,123-6,135 (-9.26%)0.20%$0 MNov 16, 2026
11Empowered Funds, LLC59,5470 (0.00%)0.20%$0 MNov 13, 2026
12Millennium Management LLC58,647-20,683 (-26.07%)0.19%$0 MNov 16, 2026
13Bank of New York Mellon Corp39,3550 (0.00%)0.13%$0 MNov 5, 2026
14Gsa Capital Partners LLP37,995+7,341 (+23.95%)0.12%$0 MNov 16, 2026
15Dimensional Fund Advisors LP35,491-562 (-1.56%)0.12%$0 MNov 4, 2026
16Allworth Financial LP34,725New0.11%$0 MNov 17, 2026
17Connor, Clark & Lunn Investment Management Ltd.27,9430 (0.00%)0.09%$0 MNov 10, 2026
18BNP Paribas Financial Markets25,400-1,064 (-4.02%)0.08%$0 MNov 12, 2026
19National Bank Of Canada /fi/25,0000 (0.00%)0.08%$0 MNov 16, 2026
20Bank Of America Corp /de/23,7890 (0.00%)0.08%$0 MNov 16, 2026
21Squarepoint Ops LLC14,941-19,816 (-57.01%)0.05%$0 MNov 9, 2026
22UBS Group AG14,315+9,280 (+184.31%)0.05%$0 MNov 10, 2026
23American Century Companies Inc13,510-4,871 (-26.50%)0.04%$0 MNov 12, 2026
24Qube Research & Technologies Ltd13,485-20,085 (-59.83%)0.04%$0 MNov 13, 2026
25Pinnacle Financial Partners, Inc.11,7960 (0.00%)0.04%$0 MNov 13, 2026
Show all 34: investors 26 to 34
Institutional investors 26 to 34 in XBiotech Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Global Advisers, LLC7,0090 (0.00%)0.02%$0 MNov 13, 2026
27Royal Bank Of Canada2,908+1,702 (+141.13%)0.01%$0 MNov 16, 2026
28McIlrath & Eck, LLC7530 (0.00%)0.00%$0 MNov 17, 2026
29Jones Financial Companies Lllp3700 (0.00%)0.00%$0 MNov 13, 2026
30Jpmorgan Chase & Co960 (0.00%)0.00%$0 MNov 12, 2026
31SBI Securities Co., Ltd.370 (0.00%)0.00%$0 MOct 22, 2026
32Tower Research Capital LLC (TRC)25New0.00%$0 MNov 16, 2026
33Larson Financial Group LLC210 (0.00%)0.00%$0 MNov 5, 2026
34Caitong International Asset Management Co., Ltd14+3 (+27.27%)0.00%$0 MOct 29, 2026

Mutual funds holding XBiotech Inc.#

13 funds hold shares worth $1 M (about 1.8% of the company). Since their previous reports 3 added shares and 3 sold, buying $0 M net.
Mutual funds holding XBiotech Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.200,182$0 M0.66%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC110,502$0 M0.36%<0.01%+8.7%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors78,591$0 M0.26%0.01%+50%Jun 30, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers59,547$0 M0.20%0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC35,154$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC27,507$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC16,960$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust13,228$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC6,066$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC5,290$0 M0.02%<0.01%+37%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust4,871$0 M0.02%<0.01%−9.3%May 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.2,660$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust282$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 13 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at XBiotech Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$855 K
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$855 K
open market only
Insiders on file
11
since
$711 K$0Oct 2026: bought $711 K (1 trades), sold $0 (0 trades)Oct 26Nov 2026: bought $143 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
XBiotech Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John SimardDirector, 10% ownerBuy+70,000$2.049$143 K4.26 MForm 4
filed John SimardDirector, 10% ownerBuy+368,524$1.930$711 K4.19 MForm 4
filed W. Thorpe McKenzieDirector, 10% ownerOption exercise+250,000$10.00$2.5 M2.81 MForm 4
filed W. Thorpe McKenzieDirector, 10% ownerShares withheld for tax-213,493$11.71$2.5 M2.60 MForm 4
filed John SimardChief Executive Officer, Director, 10% ownerSell-33,000$13.07$431 K3.82 MForm 4
filed John SimardChief Executive Officer, Director, 10% ownerSell-17,000$13.32$226 K3.86 MForm 4
filed John SimardChief Executive Officer, Director, 10% ownerSell-21,125$12.90$273 K3.87 MForm 4
filed John SimardChief Executive Officer, Director, 10% ownerSell-10,875$12.83$140 K3.96 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: XBiotech Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
315,307
1.0% of shares · 2.64 days to cover
Buybacks, Q4 2024
$0M
Q4 2024
Shares sold short, last 24 reportsAll stocks →
XBiotech Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2024Q4 2024$0M
Q3 2024Q3 2024$0M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q4 2022Q4 2023$0M
Q3 2022Q3 2023$0M

Trading halts

  • 2024-12-23 14:54 UTC, code LUDP, resumed 15:04 UTC
  • 2024-12-23 13:55 UTC, code T3, resumed 14:50 UTC

Fails to deliver

  • : 23,318 shares at $2.00
  • : 57 shares at $2.18
  • : 672 shares at $2.19
  • : 11,308 shares at $2.19
  • : 617 shares at $2.18

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

XBiotech Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.4×Price to book 0.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-65.9%Free cash flow is -65.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.49 vs -1.26Diluted EPS -1.49 in fiscal 2025 against -1.26 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$11 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-28.2%-28.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities16.0×Current ratio 16.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.1%Diluted shares up 0.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

XBiotech Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

XBiotech Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue——04.0184400——
Cost of revenue——00.75.83500——
Gross profit——03.4139.400——
Research and development47383332289.524162642
General and administrative8.34.74.76.39.4187.15.37.610
Operating expenses—423838382831213453
Operating income−56−42−38−34−25−18−31−21−34−53
Other non-operating income (expense)103.9130.9−0.45.4750−0.10.90.0
Income before tax−45−39−24−34−25−13718−21−33−53
Income tax0.2−0.00.2−0.7−8.0−1.650000
Net income attributable to shareholders−46−39−25−33−17−11669−21−33−53r
Earnings per share, basic-1.49-1.26-0.81-1.08-0.58-0.3617.17-0.59-0.95-1.63
Earnings per share, diluted-1.49-1.26-0.81-1.08-0.58-0.3614.44-0.59-0.95-1.63
Shares, weighted average (basic)303030303031393635—
Shares, weighted average (diluted)30303030303146363532
Balance sheet
Cash and cash equivalents126173200157237237715163234
Short-term investments——0600—————
Receivables—0.70.91.204.10———
Other current assets1.01.00.80.60.90.61.71.21.62.6
Current assets127175202220247326716173337
Property, plant and equipment23252526282725273010
Total assets15019922724627535481744r6367
Accounts payable1.52.22.52.42.12.52.11.71.74.4
Current liabilities7.9156.14.13.54.0602.92.88.0
Total liabilities9.7177.85.75.85.1612.92.88.0
Retained earnings−136−91−52−285.298431−238−217−183
Shareholders' equity140182219240269349756416059
Total liabilities and equity150199227246275354817446367
Shares outstanding3030303030r294236r3533
Cash-flow statement
Share-based compensation3.61.83.35.14.5133.41.71.85.6
Cash from operating activities−40−31−19−1569−65−18−17−34−46
Capital expenditure−0.3−1.3−0.4−0.6−3.5−3.7−0.2−0.1−1.4−4.7
Cash from investing activities−0.3−1.361−64−3.5−3.7675−0.1−1.4−14
Shares issued——0.0—8.0103.8—0.7—
Shares bought back—0−0.00——————
Dividends paid———0−7500———
Cash from financing activities−1010−0.00−67−410420.2332.9
Exchange-rate effect on cash3.3−5.5−0.0−1.00.71.40.10.5−0.80.3
Change in cash−47−2743−80−0.4−477699−16−2.6−57
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at XBiotech Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$30.1 M
Dr. Sushma Shivaswamy
Other top executives, average
$385 K
the CEO earned 78.3× this
$100 invested is now
—
XBiotech Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Sushma Shivaswamy$30.1 M$27.1 M$385 K—
2024Jan-Paul Simard$6.2 M$6.2 M$471 K$2
2023Jan-Paul Simard$5.6 M$5.6 M$500 K$14

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at XBiotech Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 8 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 4

XBiotech Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K/A
Directors and officersMaterial agreement8-K
Shareholder vote8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K
Directors and officers8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 26, 2026

How XBiotech Inc. compares in Biotechnology

  • Market cap$61 M · higher than 29% of 726
  • Revenue growth-78.2% · higher than 7% of 438
  • Price / book0.4× · lower than 94% of 534
  • FCF yield-65.9% · higher than 19% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
XBiotech Inc.🇺🇸$61 M——-78.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on June 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at XBiotech Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show XBiotech Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about XBiotech Inc.? Suggest a correction